#United States #Caristo Diagnostics #Heart Health #Biograph #San Mateo, Stamford

Pioneering Advances in Heart Health

In a groundbreaking partnership, Biograph, a cutting-edge preventive health clinic, has teamed up with Caristo Diagnostics to launch the first U.S. study aimed at enhancing heart disease prevention through Artificial Intelligence (AI). The study is designed to identify early cardiovascular risks in asymptomatic individuals, leveraging Caristo's novel technologies, CaRi-Heart2 and CaRi-Plaque2.

What the Study Entails

Beginning this October, Biograph will enroll 100 of its Black Tier members who are clinically eligible for participation. They will undergo detailed health assessments, including a health history questionnaire and a consultation process before imaging. Participants will then receive cardiac CT scans that utilize Caristo's technologies. This initiative marks the first time Caristo's AI-driven methods will be studied in asymptomatic patients in the United States, a group traditionally considered low risk.

The Importance of Early Detection

Dr. Michael Doney, Executive Medical Director at Biograph, emphasized that early detection of coronary inflammation is vital. “Inflammation often leads to plaque buildup, indicating potential heart disease,” he explained. This partnership aims to provide members with access to cutting-edge cardiac diagnostics that are not broadly available in the U.S.

Currently, many clinical pathways overlook inflammatory disease activity and rely heavily on plaque assessment, which can miss high-risk patients. Evidence suggests that up to twice as many fatal and non-fatal cardiac events occur in those without obstructive plaques visible on computed tomography angiography (CCTA). CaRi-Heart technology can detect such risks up to a decade in advance, even before any visible plaque forms.

A Revolutionary Technology

Caristo Diagnostics has developed game-changing detection technology that quantifies invisible coronary inflammation through cardiac CT scans. This capability allows for timely intervention and management of heart health conditions. Whereas typical methods require observable plaque for diagnosis, this innovative approach allows clinicians to identify risks much earlier. Currently, the CaRi-Heart technology is approved for use in Europe, and this U.S. study represents a pivotal step for its application in early detection practices.

Goals of the Partnership

"We chose Biograph as our initial U.S. partner due to its strong commitment to preventive healthcare and advanced imaging capabilities," remarked Professor Keith Channon, Chief Medical Officer of Caristo Diagnostics. The aim is to evaluate the efficacy of CaRi-Heart technology in a real-world setting, taking advantage of Biograph's unique patient population.

The insights gleaned from this study will contribute to global efforts designed to elevate the standard of cardiovascular care by identifying hidden risks and enabling timely intervention. Both Biograph and Caristo are dedicated to changing the landscape of heart health through personalized prevention strategies.

A Commitment to Health Revolution

“This initiative aligns perfectly with Biograph’s mission to redefine healthcare,” added Dr. Doney. The study signifies a commitment to proactive strategies that emphasize early detection and management of heart conditions, a step towards prolonging the healthspan of members.

Participants in the study will not only play a role in advancing scientific understanding but will also receive personalized care tailored to their unique health profiles. With a focus on enhancing preventive health measures, Biograph and Caristo are set to lead the charge in transforming cardiac diagnostics.

For individuals interested in more information or ready to enroll, visit Biograph's website.

About Biograph

Biograph is dedicated to pushing the boundaries of health and longevity, operating the world’s most advanced preventive health clinic. They focus on integrating the latest research with personalized medical care, establishing a human-centered approach throughout their member's journey.

About Caristo Diagnostics

Caristo Diagnostics is at the forefront of AI-powered cardiovascular detection. Originating from the University of Oxford, their innovations are paving the way for earlier detection and intervention strategies in heart health, aiming to save lives through preemptive measures and personalized care. For further details, visit Caristo's website.